Tower Research Capital LLC TRC Has $218,000 Position in Amgen Inc. (AMGN)
Tower Research Capital LLC TRC reduced its position in shares of Amgen Inc. (NASDAQ:AMGN) by 59.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,330 shares of the medical research company’s stock after selling 1,923 shares during the period. Tower Research Capital LLC TRC’s holdings in Amgen were worth $218,000 at the end of the most recent quarter.
Other large investors also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp raised its stake in shares of Amgen by 2.3% in the first quarter. Bank of New York Mellon Corp now owns 8,555,356 shares of the medical research company’s stock valued at $1,403,676,000 after buying an additional 195,200 shares in the last quarter. Schwab Charles Investment Management Inc. raised its stake in shares of Amgen by 1.6% in the first quarter. Schwab Charles Investment Management Inc. now owns 2,894,780 shares of the medical research company’s stock valued at $474,947,000 after buying an additional 45,403 shares in the last quarter. Bank of Montreal Can raised its stake in shares of Amgen by 10.5% in the first quarter. Bank of Montreal Can now owns 2,837,456 shares of the medical research company’s stock valued at $465,543,000 after buying an additional 269,586 shares in the last quarter. UBS Asset Management Americas Inc. raised its stake in shares of Amgen by 3.1% in the first quarter. UBS Asset Management Americas Inc. now owns 2,719,874 shares of the medical research company’s stock valued at $446,250,000 after buying an additional 81,362 shares in the last quarter. Finally, Swiss National Bank increased its position in Amgen by 26.5% in the first quarter. Swiss National Bank now owns 2,636,008 shares of the medical research company’s stock valued at $432,490,000 after buying an additional 551,600 shares during the last quarter. 79.12% of the stock is owned by institutional investors and hedge funds.
Shares of Amgen Inc. (NASDAQ AMGN) traded up 0.155% during trading on Tuesday, hitting $170.784. The company had a trading volume of 378,685 shares. The stock has a market capitalization of $124.62 billion, a P/E ratio of 15.556 and a beta of 1.35. Amgen Inc. has a 52 week low of $133.64 and a 52 week high of $184.21. The firm’s 50 day moving average is $174.45 and its 200-day moving average is $167.84.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, beating analysts’ consensus estimates of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The company had revenue of $5.81 billion during the quarter, compared to analyst estimates of $5.67 billion. During the same period in the prior year, the company earned $2.84 earnings per share. The firm’s revenue was up 2.1% on a year-over-year basis. Equities research analysts anticipate that Amgen Inc. will post $12.57 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Thursday, August 17th will be paid a dividend of $1.15 per share. This represents a $4.60 dividend on an annualized basis and a yield of 2.68%. The ex-dividend date is Tuesday, August 15th. Amgen’s payout ratio is presently 41.93%.
ILLEGAL ACTIVITY WARNING: “Tower Research Capital LLC TRC Has $218,000 Position in Amgen Inc. (AMGN)” was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.watchlistnews.com/tower-research-capital-llc-trc-has-218000-position-in-amgen-inc-amgn/1490590.html.
AMGN has been the subject of several research reports. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and set a $189.00 price target on shares of Amgen in a research note on Friday, June 30th. Cowen and Company reiterated an “outperform” rating and set a $209.00 price target on shares of Amgen in a research note on Wednesday, April 19th. BidaskClub upgraded Amgen from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 23rd. Jefferies Group LLC reiterated a “hold” rating and set a $180.00 price target on shares of Amgen in a research note on Monday, May 22nd. Finally, Credit Suisse Group set a $177.00 price target on Amgen and gave the stock a “hold” rating in a research note on Friday, July 14th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $186.64.
In related news, SVP Cynthia M. Patton sold 2,922 shares of the stock in a transaction that occurred on Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total transaction of $451,156.80. Following the completion of the transaction, the senior vice president now directly owns 24,214 shares of the company’s stock, valued at $3,738,641.60. The sale was disclosed in a filing with the SEC, which is available through this link. 0.20% of the stock is currently owned by corporate insiders.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.